<DOC>
	<DOCNO>NCT00375830</DOCNO>
	<brief_summary>This clinical trial study sodium fluorine-18 ( 18F NaF ) /fluorine-18 ( 18F ) fluorodeoxyglucose ( FDG ) positron emission tomography ( PET ) /magnetic resonance imaging ( MRI ) detect skeletal metastasis patient stage III-IV breast cancer stage II-IV prostate cancer . 18F NaF 18F FDG radioactive substance absorb cancerous cell allow cancer find use diagnostic procedure PET/MRI . PET/MRI procedure combine detail picture area inside body PET MRI scan may help find diagnose skeletal metastasis patient breast prostate cancer . It yet know whether 18F NaF/18F FDG PET/MRI well standard image method detect skeletal metastasis .</brief_summary>
	<brief_title>Combined 18F NaF/18F FDG PET/MRI Detection Skeletal Metastases</brief_title>
	<detailed_description />
	<mesh_term>Sodium Fluoride</mesh_term>
	<mesh_term>Fluorides</mesh_term>
	<mesh_term>Listerine</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Patient provide write informed consent Patient diagnose &gt; = stage 3 breast cancer &gt; = stage 2 prostate cancer ( and/or prostatespecific antigen [ PSA ] &gt; 10 micrograms/L ) , include patient recurrent breast prostate cancer Patient capable comply study procedure Patient able remain still duration image procedure ( one hour ) Patient ≥ 18 year old time drug administration Patient provide write informed consent Patient diagnose ≥ stage 3 breast cancer ≥ stage 2 prostate cancer ( and/or PSA &gt; 10 micrograms/L ) , include patient recurrent breast prostate cancer Patient capable comply study procedure Patient able remain still duration image procedure ( one hour ) Patient &lt; 18 year old time drug administration Patient pregnant nursing Metallic implant ( contraindicate MRI ) Renal function impairment prevent administration MRI contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>